BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Dr. Kristen Fortney is the President of BIOAGE Labs Inc, joining the firm since 2015.
What is the price performance of BIOA stock?
The current price of BIOA is $16.29, it has increased 1.68% in the last trading day.
What are the primary business themes or industries for BIOAGE Labs Inc?
BIOAGE Labs Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is BIOAGE Labs Inc market cap?
BIOAGE Labs Inc's current market cap is $722.9M
Is BIOAGE Labs Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for BIOAGE Labs Inc, including 0 strong buy, 0 buy, 5 hold, 2 sell, and 0 strong sell